Skip to main content
. Author manuscript; available in PMC: 2015 Jan 28.
Published in final edited form as: J Neurochem. 2014 Sep 19;132(1):85–98. doi: 10.1111/jnc.12934

Figure 8. PPAR agonists stimulate E-FABP expression and protect NGFDPC12 cells from PAM-LTx.

Figure 8

(A) Cells were treated with 10 μM of PPARα agonist (WY14643), PPARβ agonist (GW0742) and PPARγ agonist (GW1929) in control medium for 12 and 24 hrs. The stock solution of chemicals was made at 20 mM in DMSO. CTL: control medium with 0.05% DMSO. Relative E-FABP mRNA levels of cells upon treatments were determined at 12 and 24 hrs by real-time RT-PCR. (B) NGFDPC12 cells were treated with 300 μM PAM without PPAR agonists pretreatment (PAM), with GW0742 pretreatment (PAM+ PPAR-β), or with GW1929 pretreatment (PAM+ PPAR-γ) for 2 days. Each group was also treated with control medium without PAM. Cell viability was determined by WST-1 assay at 48 hrs. (C) siControl and siE-FABP transfected cells were treated with 10 μM GW0742 or GW0742 for 2 days before PAM-LTx experiment. Cell viability was determined by WST-1 assay at 48 hrs. The data represent mean ± SEM of three independent experiments. Significance symbols: *=p<0.05 and ***=p<0.001. Significance symbols are shown above bars when compared to control group and are shown above lines when compared between two linked groups.